Eksim Ventures
VC Fund
Istanbul, Turkey
Eksim Ventures is a VC fund in Istanbul focused on Artificial Intelligence and Software. Eksim Ventures supports potential business models and ideas by strengthening the power of technology. The firm was founded by Eksim Holding in 2021 and has 35 years of experience in smart capital.
- Total investments:
- 24
- Last investment:
- Lead investor:
- 58%
Last updated:
For AI agents: llms.txt
Industries Eksim Ventures invests in
Stages Eksim Ventures invests in
Countries Eksim Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Seed
- $447k–$3.5M
- Pre-Seed
- $150k–$2M
- Venture - Series Unknown
- $1.5M–$2.4M
Investment Focus
Industry
- Artificial Intelligence 4 (17%)
- Software 3 (13%)
- E-Commerce 3 (13%)
- Health Care 3 (13%)
- Information Technology 3 (13%)
Stage
- Seed 12 (50%)
- Venture - Series Unknown 4 (17%)
- Pre-Seed 2 (8%)
- Series A 2 (8%)
- Convertible Note 1 (4%)
Country
- Turkey 12 (50%)
- United States 3 (13%)
- United Kingdom 2 (8%)
- United Arab Emirates 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Muhammed Emre Bulut
Investment Director
|
Investment Director | Total investments: 5 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Patientdesk.ai
|
Patientdesk.ai is an AI-powered front desk platform aimed largely at dental clinics, automating patient interactions such as calls, bookings, insurance verification, and payment. | $2.8M / Seed / Apr 28, 2026 | |
PhiTech Bioinformatics
|
PhiTech Bioinformatics translates genome-wide molecular data, Transcriptomics, Epigenomics, Microbiomics into biotechnology solutions. | $2.4M / Venture - Series Unknown / Apr 08, 2026 | |
SmartAlpha
|
SmartAlpha is committed to developing products with a particular focus on ‘AI on ultrasound’. Artificial intelligence guided ultrasound interpretation product Nerveblox (www.nerveblox.com) is the first of its breed. | Venture - Series Unknown / Sep 18, 2025 | |
|
PhiTech Bioinformatics
|
PhiTech Bioinformatics translates genome-wide molecular data, Transcriptomics, Epigenomics, Microbiomics into biotechnology solutions. | Venture - Series Unknown / Sep 18, 2025 | |
EchoTwin AI
|
EchoTwin AI is a Physical AI–powered Cognitive City platform transforming how cities operate. By turning existing municipal fleets into mobile sensing platforms, we give agencies real-time visibility into road conditions, critical assets, and curbside/parking environments. Powered by AI cameras, digital twins, and proprietary vision-languagemodels, the system continuously observes the city—detecting infrastructure hazards, defects, and compliance issues—predicting failures before they escalate, and understanding context to route actions through compliant workflows. It creates work orders, evidence trails, and prioritized operator queues, then closes the loop with verification by re-checking locations to confirm fixes and quantify outcomes. The result is measurable: safer streets, faster repairs, lower operational costs, and a unified intelligence layer that moves cities from reactive, manual inspections to self-healing, auditable, and scalable municipal service delivery—systems that can truly see, think, and act. | $8M / Seed / Sep 01, 2025 | |
DefensX
|
DefensX makes sure the users are safe working anywhere on any network or device including desktops, laptops, and, iOS & Android. DefensX bundles Remote Browser Isolation, Zero Trust File Protection, and Zero Trust Credential Exposure functionalities for secure remote work. | $2.3M / Seed / May 21, 2025 | |
Virasoft
|
ViraSoft’s ambition is to be the first choice in the field of digital pathology in Turkey and in mid-term enabling to give service to the neighboring countries. Together with the R&D activities, we aim to improve the efficiency and effectivity in the pathology process and reach significant diagnosis results. | Venture - Series Unknown / May 21, 2025 | |
Albert Health
|
50% of people with chronic diseases do not take medications as prescribed. Improper medication use, especially for elderly patients, leads to hospitalizations and costs insurers billions of dollars. Current apps in the market are too complicated and difficult to use for the elderly who suffer the most from chronic diseases. Albert is a voice-basedhealth assistant which is accessible through mobile app, Amazon Alexa and Google assistant. Our machine learning algorithms create a unique conversational medication management experience. Elderly patients don’t have to text anymore. They will talk with Albert to manage their medications in an easy and effortless way. Patients can easily track health measurements, keep medical diary and set pill reminder by voice command. Furthermore, “Caregiver Mode” allows family members to manage and monitor their relatives’ treatment remotely. Albert helps elderly patients to take the right dose at the right time and help insurers to have less medical expenses, more satisfied customers. | $1.5M / Venture - Series Unknown / Feb 18, 2025 | |
Hiwell
|
Hiwell app is an online psychological counseling app that helps people without leaving their homes. | $3.5M / Seed / Jul 02, 2024 | |
Samplico
|
Samplico is a marketing platform for brands to discover new products by providing feedback on sampled products. | $1.8M / Seed / Feb 29, 2024 | |
| See all 24 investments → | |||
Co-Investors
Maxis
5 deals together
APY Ventures
4 deals together
TIBAS Ventures
3 deals together
Galata Business Angels
3 deals together
Logo Ventures
3 deals together
Ak Portfoy
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Eksim Ventures invest in?
Eksim Ventures invests primarily in Artificial Intelligence, Software and E-Commerce startups, most often at Seed and Venture - Series Unknown stage. Most of the 24 investments tracked by Shizune back companies in Turkey. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Eksim Ventures's check size?
Eksim Ventures typically joins rounds of $447k–$3.5M at Seed, $150k–$2M at Pre-Seed and $1.5M–$2.4M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Eksim Ventures participates in.
How do I contact Eksim Ventures?
Public channels for Eksim Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Eksim Ventures?
The team at Eksim Ventures includes Muhammed Emre Bulut (Investment Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
